STOCK TITAN
  1. Home
  2. News
  3. HCM

HUTCHMED (China) Limited - HCM STOCK NEWS

Welcome to our dedicated news page for HUTCHMED (China) (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on HUTCHMED (China).

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HUTCHMED (China)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HUTCHMED (China)'s position in the market.

News
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Rhea-AI Summary
HUTCHMED announces new data on compounds for cancer treatment at AACR Annual Meeting 2024, showcasing promising results for potential treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
News
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Rhea-AI Summary
HUTCHMED and Innovent Biologics announce NDA acceptance and Priority Review for fruquintinib and sintilimab combination therapy for advanced endometrial cancer. The NDA is supported by data from FRUSICA-1 Phase II study, showing promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Rhea-AI Summary
HUTCHMED (HCM) announces Phase IIIb data for savolitinib in NSCLC, showing promising results with median PFS of 13.7 months and expanded indication for treatment-naïve patients in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
News
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Rhea-AI Summary
HUTCHMED initiates Phase II/III clinical trial for sovleplenib in wAIHA patients in China, following positive Phase II data. The trial aims to confirm safety and efficacy, with the first patient dosed on March 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
clinical trial
-
News
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
Rhea-AI Summary
HUTCHMED Reports 97% Revenue Growth to $838M, FDA Approval, and NDA Review for Sovleplenib
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
none
-
News
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
Rhea-AI Summary
HUTCHMED (China) Limited announces positive results from the Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China. The trial showed a statistically significant improvement in progression-free survival and overall response rate, as well as other endpoints. The safety profile was consistent with expectations, and the combination therapy could be a promising second-line treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
clinical trial
News
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
Rhea-AI Summary
Inmagene Biopharmaceuticals exercised its option to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor. Inmagene retains rights to develop and commercialize both assets worldwide. The collaboration with HUTCHMED has allowed Inmagene to take these assets from pre-clinical to clinical development. IMG-007 is being evaluated in Phase 2a studies in two indications, while IMG-004 is being evaluated in a Phase 1 multiple ascending dose (MAD) study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
News
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
Rhea-AI Summary
HUTCHMED announced that Inmagene Biopharmaceuticals has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004, pursuant to a strategic partnership. Inmagene will be granted an exclusive license to further develop, manufacture, and commercialize these two drug candidates worldwide. HUTCHMED is entitled to receive potential payments of up to US$92.5 million for development milestones and up to US$135 million for commercial milestones, as well as royalties upon commercialization. In 2023, Inmagene initiated two global Phase IIa clinical trials for IMG-007 and completed a Phase I study for IMG-004. Dr. Weiguo Su, CEO of HUTCHMED, highlighted the progress and potential impact of the partnership on developing innovative drug candidates for patients with immunological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
partnership
-
News
HUTCHMED to Announce 2023 Final Results
Rhea-AI Summary
HUTCHMED (China) Limited will be announcing its final results for the year ended December 31, 2023 on February 28, 2024. Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 7:30 am EST on February 28, 2024, and there will also be a Chinese webcast on February 29, 2024. Both webcasts will be available live via the company website at www.hutch-med.com/event/
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none
News
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
Rhea-AI Summary
HUTCHMED (China) Limited announces the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer. This marks the first medicine to be approved under the new '1+' mechanism by the HKSAR Government, allowing drugs beneficial for life-threatening diseases to apply for registration with supporting local clinical data and recognition from relevant experts. ELUNATE® is a selective oral inhibitor of VEGF receptors -1, -2, and -3, and is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer in almost a decade. Fruquintinib has already been approved in mainland China, Macau SAR, and the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
Stock HCM logo
HUTCHMED (China) Limited

Nasdaq:HCM

HCM Rankings

#1590 Ranked by Market Cap
#118 Ranked by Stock Gains
N/A Ranked by Dividends

HCM Stock Data

3.14B
1.00B
0.13%
9.43%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
HK
Central

About HCM

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.